share_log

8-K: Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives

8-K: Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives

8-K:木薯科學宣佈執行領導層變動、加強公司治理和其他舉措
美股SEC公告 ·  07/17 09:16

Moomoo AI 已提取核心訊息

Cassava Sciences, Inc. announced significant changes in its executive leadership on July 17, 2024. Remi Barbier, the President and CEO, resigned from his roles at the company and the Board of Directors, effective September 13, 2024. Richard J. Barry, an independent director, has been appointed as the Executive Chairman and will serve as the principal executive officer until a new CEO is found. Additionally, Lindsay Burns, Ph.D., SVP of Neuroscience, has stepped down from her role, effective immediately, but will provide consulting services for a year. The company is committed to transparency and ethical business practices as it continues to develop treatments for Alzheimer's disease. These governance changes follow the redemption of warrants and the delisting of the associated trading symbols from the Nasdaq Capital Market as of May 7, 2024.
Cassava Sciences, Inc. announced significant changes in its executive leadership on July 17, 2024. Remi Barbier, the President and CEO, resigned from his roles at the company and the Board of Directors, effective September 13, 2024. Richard J. Barry, an independent director, has been appointed as the Executive Chairman and will serve as the principal executive officer until a new CEO is found. Additionally, Lindsay Burns, Ph.D., SVP of Neuroscience, has stepped down from her role, effective immediately, but will provide consulting services for a year. The company is committed to transparency and ethical business practices as it continues to develop treatments for Alzheimer's disease. These governance changes follow the redemption of warrants and the delisting of the associated trading symbols from the Nasdaq Capital Market as of May 7, 2024.
Cassava Sciences, Inc.於2024年7月17日宣佈其高管團隊發生重大變革。總裁兼首席執行官Remi Barbier自2024年9月13日起辭去擔任董事會成員和公司的職務。獨立董事Richard J. Barry被任命爲執行主席,並擔任首席執行官,直至找到新的CEO。此外,神經科學高級副總裁Lindsay Burns博士已從其職位上辭職,並立即提供1年的諮詢服務。該公司致力於透明和道德的業務實踐,繼續爲治療阿爾茨海默症進行研發。這些治理變化是在贖回認股權和截至2024年5月7日從納斯達克資本市場除牌之後發生的。
Cassava Sciences, Inc.於2024年7月17日宣佈其高管團隊發生重大變革。總裁兼首席執行官Remi Barbier自2024年9月13日起辭去擔任董事會成員和公司的職務。獨立董事Richard J. Barry被任命爲執行主席,並擔任首席執行官,直至找到新的CEO。此外,神經科學高級副總裁Lindsay Burns博士已從其職位上辭職,並立即提供1年的諮詢服務。該公司致力於透明和道德的業務實踐,繼續爲治療阿爾茨海默症進行研發。這些治理變化是在贖回認股權和截至2024年5月7日從納斯達克資本市場除牌之後發生的。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息